Prolonged survival of stage IV malignant mixed mullerian tumor of the ovary after carboplatin, mesna, ifosfamide, and cis-platin chemotherapy: Case report

Journal of Chemotherapy

Volumn 10, Issue 5, 1998, Pages 418-421

  Di Vagno, G ^a,b   Cormio, G ^a   Loverro, G ^a   Melilli, G A ^a   Di Gesu G ^a   Selvaggi, L ^a  

^a UNIVERSITY OF BARI   (Italy)

^b NONE   (Italy)

Author keywords

Chemotherapy; Ovarian cancer; Ovarian MMMT

Indexed keywords

CARBOPLATIN; CISPLATIN; IFOSFAMIDE; MESNA;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; FEMALE; HUMAN; MIXED MULLERIAN TUMOR; TREATMENT OUTCOME;

EID: 0031792759     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.5.418     Document Type: Article

References (25)

1. Ostor A. Genital sarcomas: pathology. In: Surgical Gynecologic Oncology, E. Burghardt, Ed, Stuttgart: Thieme, 1994: 397-408.
2. Barwick K, Livolsi V. Malignant mixed mesodermal tumors of the ovary. Am J Surg Pathol 1980; 4: 37-42.
3. Cznerobilsky B, LaBarre G. Carcinosarcoma and mixed mesodermal tumor of the ovary. A clinicopathologic analysis of nine cases. Obstet Gynecol 1968; 31: 21-32.
4. Anderson B, Turner DA, Benda J. Ovarian sarcoma. Gynecol Oncol 1987; 26: 183-192.
5. Terada KY, Johnson TL, Hopkins M, Roberts J. Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas. Gynecol Oncol 1989; 32: 228-232.
6. Chang J, Sharpe JC, A'Hern RP, et al. Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Ann Oncol 1995; 6: 755-758.
7. Morrow CP, d'Ablaing G, Brady LW, Blessing JA, Hreshchyshyn MM. A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: A gynecologic oncology group study. Gynecol Oncol 1984; 18: 278-292.
8. Hernandez W, Di Saia PJ, Morrow CP, Townsend DE. Mixed mesodermal sarcoma of the ovary. Obstet Gynecol 1977; 49: 595-635.
9. Dictor M. Malignant mixed mesodermal tumor of the ovary: A report of 22 cases. Obstet Gynecol 1985; 65: 720-724.
10. Plaxe SC, Dottino PR, Goodman HM, Deligdisch L, Idelson M, Cohen CJ. Clinical features of advanced ovarian mixed mesodermal tumors and treatment with doxorubicin and cis-platinum-based chemotherapy. Gynecol Oncol 1990; 37: 244-247.
11. Hanjani P, Petersen RO, Lipton SE, Nolte SA. Malignant mixed mesodermal tumors and carcinosarcoma of the ovary: Report of eight cases and review of the literature. Obstet Gynecol Surv 1983; 38: 537-545.
12. Fenn ME, Abell MR. Carcinosarcoma of the ovary. Am J Obstet Gynecol 1971; 110: 1066-1074.
13. Patsner B, Greenberg S, Mesna, doxorubicin, ifosfamide, and dacarbazine chemotherapy for ovarian mixed mul-lerian sarcoma: Report of four cases. Gynecol Oncol 1995; 58: 386-388.
14. Lele SB, Piver S, Barlow JJ. Chemotherapy in management of mixed mesodermal tumors of the ovary. Gynecol Oncol 1980; 10: 298-302.
15. Carlson JA, Edwards C, Wharton JT, Gallagher HS, Delclos L, Rutledge F. Mixed mesodermal sarcoma of the ovary. Treatment with combined radiation therapy and chemotherapy. Cancer 1983; 52: 1473-1477.
16. Morrow CP, Bundy BN, Hoffman J, Sutton G, Homesley H. Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary. Am J Clin Oncol 1986; 9: 24-26.
17. Anderson WA, Young DE, Peters WA et al. Platinum-based chemotherapy for malignant mixed mesodermal tumors of the ovary. Gynecol Oncol 1989; 32: 319-322.
18. Suggs CL, Lee JL, Choi H, et al. Malignant mixed mesodermal tumors of the ovary: A report of 13 cases. Am J Clin Oncol 1988; 11: 12-16.
19. Simon SR, Wang SE, Uhl M, Shackney S. Complete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide, and dacarbazine. Gynecol Oncol 1991; 41: 161-166.
20. Bramwell V, Quirt I, Warr D, et al. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. J Natl Cancer Inst 1989; 81: 1496-1499.
21. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989; 7: 1208-1216.
22. Moore M, Fine S, Sturgeon J. Malignant mixed mesodermal (MMMT) tumors of the ovary: the Princess Margaret Hospital (PMH) experience. J Clin Oncol 1986; 5: 114.
23. Sutton GP, Blessing JA, Rosenshein N, et al. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncologic Group study ). Am J Obstet Gynecol 1989; 161: 309-313.
24. Leone B, Lorusso V, Di Vagno G, et al. A combination of carboplatin, cis-platin and ifosfamide in advanced ovarian cancer. A phase I-II study. Sixth International Congress on Anti-Cancer Treatment, Paris, February 6-9, 1996; 129 abstr.
25. Van Rijswijk R, Tognon G, Burger CW, Baak JP, Kenemans P, Vermorken JB. The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract. Int J Gynecol Cancer 1994; 4: 52-60.